Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
OTC:GZPHF

Watchlist Manager
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Logo
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
OTC:GZPHF
Watchlist
Price: 2.34 USD Market Closed
Market Cap: $6.3B

Wall St Price Targets

GZPHF Price Targets Summary
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

Wall Street analysts forecast GZPHF stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GZPHF is 3.01 USD with a low forecast of 1.86 USD and a high forecast of 4.26 USD.

Lowest Forecast
Price Target
1.86 USD
21% Downside
Average Forecast
Price Target
3.01 USD
29% Upside
Highest Forecast
Price Target
4.26 USD
82% Upside
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Competitors:
Price Targets

Revenue
Forecast

15% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
15% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 3 years is 5%.

Gross Profit
Forecast

10% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
10% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 10%. The projected CAGR for the next 2 years is 5%.

Operating Income
Forecast

13% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss
13% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 13%. The projected CAGR for the next 3 years is 8%.

Pre-Tax Income
Forecast

12% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
12% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 12%. The projected CAGR for the next 3 years is 7%.

Net Income
Forecast

11% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
11% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 7%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is GZPHF's stock price target?
Price Target
3.01 USD

According to Wall Street analysts, the average 1-year price target for GZPHF is 3.01 USD with a low forecast of 1.86 USD and a high forecast of 4.26 USD.

What is the Revenue forecast for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd?
Projected CAGR
5%

Over the last 13 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 3 years is 5%.

What is the Gross Profit forecast for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd?
Projected CAGR
5%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 10%. The projected CAGR for the next 2 years is 5%.

What is the Operating Income forecast for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd?
Projected CAGR
8%

Over the last 13 years, the compound annual growth rate for Operating Income has been 13%. The projected CAGR for the next 3 years is 8%.

What is the Pre-Tax Income forecast for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd?
Projected CAGR
7%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 12%. The projected CAGR for the next 3 years is 7%.

What is the Net Income forecast for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd?
Projected CAGR
7%

Over the last 13 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 7%.

Back to Top